Post-therapy serum prostate-specific antigen level and survival in patients With androgen-independent prostate Cancer

• Published in: JNCI : Journal of the National Cancer Institute Vol. 91; no. 3; pp. 244 - 251
• Main Authors: SCHER, H. I, KELLY, W. M. K, ZHANG, Z.-F, OUYANG, P, MIN SUN, SCHWARTZ, M, DING, C, WEIPING WANG, HORAK, I. D, KREMER, A. B
• Format: Journal Article
• Language: English
• Published: Cary, NC Oxford University Press 03.02.1999; Oxford Publishing Limited (England)
• Subjects: Aged; Aged, 80 and over; Biological and medical sciences; Humans; Male; Medical sciences; Middle Aged; Multivariate Analysis; Nephrology. Urinary tract diseases; Prognosis; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - immunology; Prostatic Neoplasms - therapy; Reproducibility of Results; Risk Factors; Survival Analysis; Therapy; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Human; Correlation; Urinary system disease; Prognosis; Prostate disease; Male; Tumoral marker; Malignant tumor; Radiotherapy; Prostate specific antigen; Phase II trial; Male genital diseases; Prostate; Survival curve; Quantitative analysis

With an hypothesis that post-chemotherapy changes in serum prostate-specific antigen (PSA) levels might serve as a surrogate marker for assessing prostate cancer outcome (i.e., survival), we studied the relationship between pretherapy and post-therapy prognostic factors and survival in patients with...